Near-infrared fluorescent probe-mediated high-throughput discovery of a natural β-galactosidase inhibitor for senescence-associated atherosclerosis therapy
Journal of Pharmaceutical Analysis · 2026-10 · 16 (10) · 101659
DOI: 10.1016/j.jpha.2026.101659 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-10. Verfasst von Yujuan Qin und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical and Health Science and Technology Development Project of Shandong Province, National Natural Science Foundation of China, Shandong Province Natural Science Foundation.
Abstract (Originalsprache)
Atherosclerosis (AS), a disease associated with aging, significantly compromises the health and quality of life of patients. β-galactosidase (β-gal), a key cell senescence biomarker, shows significantly increased activity in senescent cells. Upregulated β-gal in senescent cells amplifies a proinflammatory senescence-associated secretory phenotype (SASP), driving cellular dysfunction, monocyte recruitment, foam cell formation, and extracellular matrix remodeling, thereby promoting atherogenesis. Inhibiting β-gal activity is a potential strategy for delaying AS and other aging-related diseases. Herein, we designed and synthesized a novel near-infrared fluorescent probe activated by β-gal (NFP-gal). This probe exhibited high sensitivity and selectivity with low cytotoxicity and biotoxicity under the tested conditions. We used this fluorescence-guided screening method to evaluate the β-gal inhibitory activity of 58 traditional Chinese medicines (TCMs) and identified Arnebia euchroma (AE) as a strong candidate. Through targeted separation and identification of complex components in AE using ultra-high-performance liquid chromatography with quadrupole orbitrap high-resolution mass spectrometry (UHPLC-Q-orbitrap-HRMS), we identified β,β-dimethyl-acryl-alkannin (DMAA) as a novel β-gal inhibitor. The pharmacodynamic effects of this compound were validated through in vitro cellular imaging using senescent cell and foam cell models, real-time in vivo fluorescence tracking in zebrafish models of AS, and histopathological analysis using apolipoprotein E-deficient (ApoE -/-) mice with high-fat diet (HFD)-induced AS. The findings confirmed the therapeutic potential of DMAA in mitigating senescence-associated vascular dysfunction. This study comprehensively evaluated the use of β-gal-based probes and natural compounds to suppress aging-related processes, highlighting their therapeutic implications for AS and other aging-associated diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
- Beijing Hton Co., Ltd., Beijing, 100010, China.
- Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
- College of Veterinary Medicine, Yunnan Agricultural University, Yunan, 650500, China.
- Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
- Shandong Key Laboratory of Digital Traditional Chinese Medicine, Key Laboratory of Traditional Chinese Medicine Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Jinan, 250355…
Förderung
- Medical and Health Science and Technology Development Project of Shandong Province
- National Natural Science Foundation of China
- Shandong Province Natural Science Foundation
Zitieren
APA
Qin, Y., Li, N., Yang, W., Wu, Y., Tang, Z., Xin, J., & Jiang, H. (2026). Near-infrared fluorescent probe-mediated high-throughput discovery of a natural β-galactosidase inhibitor for senescence-associated atherosclerosis therapy. Journal of Pharmaceutical Analysis, 16(10), 101659. https://doi.org/10.1016/j.jpha.2026.101659
Vancouver
Qin Y, Li N, Yang W, Wu Y, Tang Z, Xin J, et al. Near-infrared fluorescent probe-mediated high-throughput discovery of a natural β-galactosidase inhibitor for senescence-associated atherosclerosis therapy. Journal of Pharmaceutical Analysis. 2026;16(10):101659. doi:10.1016/j.jpha.2026.101659
BibTeX
@article{Qin2026,
author = {Qin, Yujuan and Li, Ning and Yang, Wenjie and Wu, Yi and Tang, Zhixin and Xin, Junhong and Jiang, Haiqiang},
title = {Near-infrared fluorescent probe-mediated high-throughput discovery of a natural β-galactosidase inhibitor for senescence-associated atherosclerosis therapy},
journal = {Journal of Pharmaceutical Analysis},
year = {2026},
volume = {16},
number = {10},
pages = {101659},
doi = {10.1016/j.jpha.2026.101659}
}
EUVIMED